Cyclophosphamide

Bile Duct Cancer

Imugene LimitedSmall moleculePhase 2Active

B

60/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 45/ 100
Competitive Position: 89/ 100

Competitive context

22 Active assets in the Bile Duct Cancer cohort.

Asset / Sponsor	Phase	Rating
Eloxatin Lisata Therapeutics, Inc.	Phase 2	BB
CIS-DIAMMINEDICHLOROPLATINUM II Lisata Therapeutics, Inc.	Phase 2	BB
Dfn-15 Seoul National University Hospital	Phase 4	B
Pembrolizumab Imugene Limited	Phase 2	B
FLUOROURACILUM Lisata Therapeutics, Inc.	Phase 2	B

View all 35 →

Same molecule, other indications

Cyclophosphamide is also rated in:

adult acute lymphoblastic leukemiaDormant

BBB

Indicative ·

79 / 100

mycosis fungoidesDormant

BBB

Indicative ·

78 / 100

B-cell childhood acute lymphoblastic leukemiaDormant

BBB

Indicative ·

78 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.